KWM
RNAC icon

Kingsview Wealth Management’s Cartesian Therapeutics RNAC Stock Holding History

Kingsview Wealth Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-370
Closed -$50K – 1002
2021
Q1 		$50K Sell
370
-10
-3% -$1.24K ﹤0.01% 800
2020
Q4 		$35K Buy
+380
New +$33K ﹤0.01% 689

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kingsview Wealth Management's RNAC Position: Q2 2021 in Review

Kingsview Wealth Management sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 370 shares — an estimated $50K sold.

Kingsview Wealth Management first reported a position in RNAC in Q4 2020 and held it in 2 quarters. The position peaked at $50K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • Kingsview Wealth Management reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Kingsview Wealth Management sold 370 Cartesian Therapeutics shares in Q2 2021, an estimated $50K.
  • Kingsview Wealth Management first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 2 quarters.
  • Kingsview Wealth Management's Cartesian Therapeutics position peaked at $50K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Kingsview Wealth Management's 13F filing for Q2 2021, filed 17 Aug 2021.